Home › Trials › NCT07080567
Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 18 and up

Maraviroc to improve arm and hand movement after ischemic stroke

Official title: Maraviroc for Stroke Recovery (MASTER): A Phase 2 Double-Blind Placebo-Controlled Randomized Clinical Trial

Run by University Hospital, Geneva · NCT07080567 · Data updated 2026-11-12

This trial will test whether maraviroc, started soon after ischemic stroke, helps people with partial arm weakness regain motor skills over the first three months.

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment80 (estimated)
SponsorUniversity Hospital, Geneva
Academic / other
Locations1 site (Geneva)
StatusRecruiting
StartedJuly 14, 2025
Main results expectedDecember 2027
Study endsDecember 2027
Registry record updatedAugust 12, 2025
Trial IDNCT07080567 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18) with acute ischemic stroke within five days of onset, unilateral incomplete upper-limb paresis (FMA-UE <63) and residual voluntary finger extension >10°, who can give informed consent and attend follow-up visits are ideal candidates.

Probably not a fit

Patients unlikely to benefit include those with pre-stroke disability (mRS >2), other diseases affecting motor function (e.g., Parkinson's, ALS), complete paralysis without finger extension, significant liver or renal disease, pregnancy, or inability to attend the single-center visits.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

MASTER is a single-center, double-blind, randomized, placebo-controlled phase II trial enrolling 80 adults with recent ischemic stroke and incomplete unilateral upper-limb paresis. Participants are randomized to receive maraviroc or placebo daily for 90 days, starting within five days of stroke onset, and are followed with clinical motor tests, biometrics, and brain imaging at baseline, day 90, and at six months. The trial measures motor function and motor learning with standardized scales and performance tests and collects imaging to relate clinical changes to infarct size and neuroplasticity. The design tests whether CCR5 antagonism can reduce infarct-related damage and enhance recovery when combined with usual care.

Why it matters

Potential benefit: If successful, maraviroc could improve arm and hand function after stroke and increase independence in daily activities.

How similar studies have gone: Maraviroc and other CCR5 antagonists have shown behavioral and neuroplasticity benefits in animal stroke models, but human clinical evidence is limited and this randomized trial is among the first to test the approach.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Informed consent as documented by signature
* ≥18 years at time of signing of informed consent
* Acute ischemic stroke.
* Stroke onset \< 7 days from randomization.
* Contralateral, unilateral, incomplete upper limb paresis, incl. :
* FMA-UE \< 63/66
* Residual voluntary finger extension (VFE) of \> 10 degrees

Exclusion Criteria:

* Pregnancy/lactation or positive pregnancy test in women of childbearing age
* Pre-stroke handicap (mRS \> 2)
* Diseases affecting motor function (e.g., Parkinson's Disease, Amyotrophic Lateral Sclerosis (ALS))
* Participation in another study with investigational medicinal product within 30 days preceding and during the present study
* Enrolment of the investigator, his/her family members, employees, or other dependent persons
* Known hypersensitivity to Maraviroc, Mannitol, peanuts, or soy
* History of significant liver disease, hepatitis, elevated liver function tests (\> 1.5 upper limit of normal)
* History of significant renal disease or End Stage Renal Disease/dialysis, acute renal injury, Creatinine Clearance (CrCl \< 30ml/min/1.73m2)
* Patients with cardiovascular comorbidities and risk for orthostatic hypotension
* HIV infection
* Concomitant use of strong CYP3A4 inhibitors or inducers

Where it's running

  • Geneva University Hospital
    Geneva, Switzerland     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Ischemic Stroke 314Stroke 1573Stroke, Acute 68University Hospital, Geneva 70
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.